

Figure 1(A)




Figure 1(B)




Figure 2




Figure 3(A)




Figure 3(B)




Figure 4(A)

% Reduction of lymphocytes in whole blood at 5 hr




Figure 4(B)




Figure 4(C)

% Reduction of lymphocytes in whole blood at 5 hr




Figure 4(D)




Figure 5(A)




Figure 5(B)




Figure 5(C)




Figure 5(D)




Figure 5(E)




Figure 5(F)




Figure 5(G)




Figure 5(H)




Figure 6




Figure 7(A)




Figure 7(B)




Figure 7(C)




Figure 8(A)




Figure 8(B)




Figure 9(A)




Figure 9(B)




Figure 10(A)




Figure 10(B)




Figure 11(A)




Figure 11(B)




Figure 11(C)




Figure 12**Antibody 4133**

SEQ ID NO: 1	CDRH1	GFSFSGNYMC
SEQ ID NO: 2	CDRH1 variant	GFSFSGNYMS
SEQ ID NO: 3	CDRH2	CLYTGSSGSTYYASWAKG
SEQ ID NO: 4	CDRH2 variant	SLYTGSSGSTYYASWAKG
SEQ ID NO: 5	CDRH3	DLGYEIDGYGGL
SEQ ID NO: 6	CDRH3 variant 1	DLGYEIDSYGGL
SEQ ID NO: 7	CDRH3 variant 2	DLGYEIDAYGGL
SEQ ID NO: 8	CDRH3 variant 3	DLGYEIDTYGGL
SEQ ID NO: 9	CDRL1	QASQSVYNNNLS
SEQ ID NO: 10	CDRL1 variant 1	QASQSVYNNNSLS
SEQ ID NO: 11	CDRL1 variant 2	QASQSVYNNNQLS
SEQ ID NO: 12	CDRL1 variant 3	QASQSVYNNNNLA
SEQ ID NO: 13	CDRL2	DASKLAS
SEQ ID NO: 14	CDRL3	LGGYSSGWYFA

SEQ ID NO: 15 Rabbit antibody 4133 VL region

AQVLTPSP VSAVGGTVS ISCQASQSVY NNNNLSWYQQ KPGQPPKLLI YDASKLASGV
 PSRFKSGSG TQFTLTISGV QCDDAATYYC LGGYSSGWY FAFGGGTKV VK

SEQ ID NO: 16 Rabbit antibody 4133 VH region

QEQLVESGGG LVQPEGSRTL TCTASGFSFS GNYMCWVRQ APGKGLEWIG CLYTGSSGST
 YYASWAKGRF TISKTSSTTV TLQMTSLTAA DTATYFCARD LGYEIDGYG GLWGQGTILTV SS

SEQ ID NO: 17 4133 gL7 V-region – IGKV1D-13 framework

AQVLTPSPSS LSASVGDRVT ITCQASQSVY NNNNLSWYQQ KPGKAPKLLI YDASKLASGV
 PSRFKSGSG TQFTLTISL QPEDFATYYC LGGYSSGWY FAFGGGTKVE IK

SEQ ID NO: 18 4133 gL1 V-region – IGKV1D-13 framework

AQVLTPSPSS LSASVGDRVT ITCQASQSVY NNNNLAWYQQ KPGKAPKLLI YDASKLASGV
 PSRFKSGSG TQFTLTISL QPEDFATYYC LGGYSSGWY FAFGGGTKVE IK

SEQ ID NO: 19 4133 gH1 V-region – IGHV3-21 framework

EVQLVESGGG LVKPGGSLRL SCAASGFSFS GNYMCWVRQ APGKGLEWIG CLYTGSSGST
 YYASWAKGRF TISKDSAKTS VYLQMNLSRA EDTAVYYCAR DLGYEIDGYG GLWGQGTILTV VSS

SEQ ID NO: 20 4133 gH4 V-region – IGHV3-21 framework

EVQLVESGGG LVKPGGSLRL SCAASGFSFS GNYMSWVRQ APGKGLEWIG SLYTGSSGST
 YYASWAKGRF TISKDSAKTS VYLQMNLSRA EDTAVYYCAR DLGYEIDGYG GLWGQGTILTV VSS

SEQ ID NO: 21 4133 gH1 V-region – IGHV4-4 framework

EVQLQESGPG LVKPSGTLRL TCAASGFSFS GNYMCWVRQ PPGKGLEWIG CLYTGSSGST
 YYASWAKGRV TISKDSKSTQ VSLKLSSVTA ADTAVYYCAR DLGYEIDGYG GLWGQGTILTV VSS

SEQ ID NO: 22 4133 gH3 V-region – IGHV4-4 framework

EVQLQESGPG LVKPSGTLRL TCAASGFSFS GNYMSWVRQ PPGKGLEWIG SLYTGSSGST
 YYASWAKGRV TISKDSKSTQ VSLKLSSVTA ADTAVYYCAR DLGYEIDGYG GLWGQGTILTV VSS

Figure 12 continued**Antibody 6294**

SEQ ID NO: 23 - CDRH1	GYTFTSYTMH
SEQ ID NO: 24 - CDRH2	YINPSSGYTEYNQKFKD
SEQ ID NO: 25 - CDRH3	VG <u>D</u> GFYPSWLAY
SEQ ID NO: 26 - CDRH3 variant 1	VGDSFYPSWLAY
SEQ ID NO: 27 - CDRH3 variant 2	VGDAFYPSWLAY
SEQ ID NO: 28 - CDRH3 variant 3	VGDTFYPSWLAY
SEQ ID NO: 29 - CDRL1	KASQSVRNDVA
SEQ ID NO: 30 - CDRL2	YASKRYT
SEQ ID NO: 31 - CDRL3	QQDYSSPTT

SEQ ID NO: 32 - mouse antibody 6294 VL region

DIQMTQSPKF LLVSAGDRV ITCKASQSVR NDVAWYQQKPGQSPKLLIFY ASKRYTGVPD
 RFTGSGYGTDTFTTISTVQA EDLAVYFCQQ DYSSPTTFGG GTKLEIK

SEQ ID NO: 33 - mouse antibody 6294 VH region

EVQLVESGAE LARPGASVKM SCKASGYTFT SYTMHWVKQR PGQGLEWIGY INPSSGYTEY
 NQKFKDKTTT TADKSSSTAY LQLSSLTSED SAVYYCARVG DGFYPSWLAY WGQGTTLTVSS

SEQ ID NO: 34 - 6294 gH2 V-region - IGHV3-48 framework

EVQLVESGGG LVQPGGSLRL SCAASGYTFT SYTMHWVRQA PGQGLEWIGY INPSSGYTEY
 NQKFKDRFTI SADKAKSSLY LQMNSLRDED TAVYYCARVG DGFYPSWLAY WGQGTTLTVSS

SEQ ID NO: 35 - 6294 gH4 V-region - IGHV1-69 framework

EVQLVQSGAE VKKPGSSVKV SCKASGYTFT SYTMHWVRQA PGQGLEWIGY INPSSGYTEY
 NQKFKDRVTI TADKSTSTAY MELSSLRSED TAVYYCARVG DGFYPSWLAY WGQGTTLTVSS

SEQ ID NO: 36 - 6294 gL2 V-region - IGKV1D-33 framework

DIQMTQSPSS LSASVGDRV ITCKASQSVR NDVAWYQQKPGKAPKLLIFY ASKRYTGVPD
 RFTGSGYGTDTFTTISSLQP EDIAVYFCQQ DYSSPTTFGG GTKVEIK

SEQ ID NO: 37 - 6294 gL3 V-region - IGKV4-1 framework

DIVMTQSPDS LAVSLGERAT INCKASQSVR NDVAWYQQKPGQPKLLIFY ASKRYTGVPD
 RFTGSGYGTDTFTTISSLQA EDVAVYFCQQ DYSSPTTFGG GTKVEIK

SEQ ID NO: 38 - 4133-6294 BYbe heavy chain

QEQLVESGGGLVQPEGSLLTCTASGFSFSGNYMCWVRQAPGKGLEWIGCLYTGSSTYYASWAKGRFTISK
 SSTTVTLQMTSLTAADTATYFCARDLGYEIDGYGGLWGQGTTLTVSSGQPKAPSVFPLAPCCGDTPSSTVTLGCL
 VKGYLPEPVTVTWNSGTLTNGVTRTFPSVRQSSGLYSLSSVSVTSSSQPVTNCNVAHPATNTKVDKTVAPSTCSKP
 GGGGSGGGSEVQLVESGAELARPGASVKMSCKASGYTFTSYTMHWVKQRPGQCLEWIGYINPSSGYTEYNQKFK
 DKTTLTADKSSSTAYLQLSSLTSEDSAVYYCARVGDGFYPSWLAYWGQGTTLTVSSGGGGSGGGSGGGSGGGG
 SDIQMTQSPKFLLSAGDRVITCKASQSVRNDVAWYQQKPGQSPKLLIFYASKRYTGVPDRFTGSGYGTDTFTT
 ISTVQAEDLAVYFCQQDYSSPTTFGGCGTKLEIK

Figure 12 continued**SEQ ID NO: 39****4133-6294 BYbe light chain**

AQVLTQTPSPVSAVVGTVSISQASQSVYNNNNLSWYQQKPGQPPKLLIYDASKLASGVPSRFGSGSGTQFTL
 TISGVQCDDAATYYCLGGYSSGWYFAFGGGTKVVVKRTPVAPTVLIFPPAADQVATGTVTIVCVANKYFPDVT
 TWEVDGTTQTGTGIENSKTPQNSADCTYNLSSTLTSTQYNHKEYTCKVTQGTTSVVQSFNRGDC

SEQ ID NO: 40 - CD45 Domains 1-4 with TEV cleavage site and 10-Histidine tag

KPTCDEKYANITVDYLYNKETKLF TAKLVNENVECGNNTCTNNEVHNLT ECKNASVSISHNSCTAPDKTLILDV
 PPGVEKFQLHDCTQVEKADTTICLKWKNIETFTCDTQNTYRFQCGNMIFDNKEIKLENLEPEHEYKCDSEILYN
 NHKFTNASKIIKTDFGSPGEPQIIFCRSEAAHQGVITWNPQRSFHNFTLCYIKETEKDCNLNDKNLIK YDLQNL
 KPYTKYVLSLHAYIIAKVQRNGSAAMCHFTTKSAPPSQVWNMTVSMTSDNSMHVKCRPPDRNGPHERYHLEVEA
 GNTLVRNESHKNCDFRVKDLQYSTDYTFKAYFHNGDYPGEPFILHHSTSGTKENLYFQGHHHHHHHHHH

SEQ ID NO: 41 - Human CD45

MYLWLKLLAF GFAFLDTEVF VTGQSPTSP TGLTTAKMPS VPLSSDPLPT HTTAFSPAST
 FERENDFSET TTSLSPDNTS TQVSPDSL DN ASAFNTTGVS SVQTPHLPTH ADSQTPSAGT
 DTQTFSGSAA NAKLNPTPGS NAISDVPGER STASTFPTDP VSPLTTTTLSL AHHSSAALPA
 RTSNTTITAN TSDAYLNASE TTTLSPSGSA VISTTTIATT PSKPTCDEKY ANITVDYLYN
 KETKLF TAKL NVNENVECGN NTCTNNEVHN LTECKNASVS ISHNSCTAPD KTLILDVPPG
 VEKFLHDCT QVEKADTTIC LKWKNIETFT CDTQNTYRF QCGNMIFDNK EIKLENLEPE
 HEYKCDSEIL YNNHKFTNAS KIIKTDFGSP GEPQIIFCRS EAAHQGVITW NPPQRSFHN
 TFCYIKETEK DCLNLDKNLI KYDLQNLKPY TKYVLSLHAY IIAKVQRNGS AAMCHFTTKS
 APPSQVWNMT VSMTSDNSMH VKCRPPDRN GPHERYHLEV EAGNTLVRNE SHKNCDFRVK
 DLQYSTDYTF KAYFHNGDYP GEPFILHHST SYNSKALIAF LAFLIIVTSI ALLVVLYKIY
 DLHKRSCNL DEQQELVERD DEKQLMNVEP IHADILLETY KRKIADEGRL FLAEFQSIPR
 VFSKFPIKEA RKPFNQKNR YVDILPYDYN RVELSEINGD AGSNYINASY IDGFKEPRKY
 IAAQGPRDET VDDFWRMIWE QKATVIVMT RCEEGNRNKC AEYWPSMEEG TRAFGDVVVK
 INQHRCPDY IIQKLNI VNK KEKATGREVT HIQFTSWPDH GVPEDPHLLL KLRRRVNAFS
 NFFSGPIVH CSAGVGRGTG YIGIDAMLEG LEAENKVDVY GYVVKLRQR CLMVQVEAQY
 ILIHQALVEY NQFGETEVL SELHPYLHNM KKRDPSEPS PLEAEFQRLP SYRSWRTQHI
 GNQEENKSKN RNSNVI PYDY NRVPLKHELE MSKESEHSD ESSDDSDSE EPSKYINASF
 IMSYWKPEVM IAAQGPKET IGDFWQMIFQ RKVKVIVMLT ELKHGDQEIC AQYWGEKQT
 YGDIEVDLKD TDKSSTYTLR VFELRH SKRK DSRTVYQYQY TNWSVEQLPA EPKELISMIQ
 VVKQKLPQKN SSEGNKHHKS TPLLIHCRDG SQQTGIFCAL LNLLESAETE EVVDIFQVVK
 ALRKARPGMV STFEQYQFLY DVIAS TYPAQ NGQVKKNHQ EDKIEFDNEV DKVKQDANCV
 NPLGAPEKLP EAKEQAEGSE PTSGTEGPEH SVNGPASPAL NQGS

SEQ ID NO: 115 - 4133 Light chain

AQVLTQTPSPVSAVVGTVSISQASQSVYNNNNLSWYQQKPGQPPKLLIYDASKLASGVPSRFGSGSGTQFTL
 TISGVQCDDAATYYCLGGYSSGWYFAFGGGTKVVVKRTVAAPSVFIFPPSDEQLKSGTASVCLLNNFYPREAK
 VQWKVDNALQSGNSQESVTEQDSKDYSLSTLTLSKADYEKHKVYACEVTHQGLSPVTKSFNRGEC

SEQ ID NO: 116 - 4133 IgG4P FALA

QEQLVESGGGLVQPEGLTLTCTASGFSFSGNYMCWVRQAPGKLEWIGCLYTGSSGSTYYASWAKGRFTISK
 SSTVTLTQMTSLTAADTATYFCARDLGYEIDYGGLWGQGTLVTVSSASTKGPSVFPLAPCSRSTSESTAALGCL

VKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGKTYTCNVDHKPSNTKVDKRVESKYG
 PPCPPCPAPEAAGGPSVFLFPPKPKDTLMI SRTPEVTCVVVDVSQEDPEVQFNWYVDGVEVHNAKTKPREEQFNS
 TYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTSKAKGQPREPQVYTLPPSQEEMTKNQVSLTCLVKGFY
 PSDIAVEWESNGQPENNYKTTPVLDSDGSFFLYSRLTVDKSRWQEGNVFSCSMHEALHNHYTQKSLSLGLGK

SEQ ID NO: 117 - 4133 IgG4P FALA Knob

QEQLVESGGGLVQPEGSLLTCTASGFSFSGNYMCWVRQAPGKGLEWIGCLYTGSSGSTYYASWAKGRFTISK
 SSTTVTLQMTSLTAADTATYFCARDLGYEIDGYGGLWGQGTLLVTVSSASTKGPSVFPLAPCSRSTSESTAALGCL
 VKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGKTYTCNVDHKPSNTKVDKRVESKYG
 PPCPPCPAPEAAGGPSVFLFPPKPKDTLMI SRTPEVTCVVVDVSQEDPEVQFNWYVDGVEVHNAKTKPREEQFN
 STYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTSKAKGQPREPQVYTLPPSQEEMTKNQVSLWCLVKG
 FYPSDIAVEWESNGQPENNYKTTPVLDSDGSFFLYSRLTVDKSRWQEGNVFSCSMHEALHNHYTQKSLSLGLG
 K

SEQ ID NO: 118 - 6294 Light chain

DIQMTQSPKFLLSAGDRVITITCKASQSVRNDVAWYQQKPGQSPKLLIFYASKRYTGVPDRFTGSGYGTDFTFI
 STVQAEDLAVYFCQQDYSSPTTFGGGTKLEIKRTVAAPSVFI FPPSDEQLKSGTASVCLLNFFYPREAKVQWKV
 DNALQSGNSQESVTEQDSKSTYLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC

SEQ ID NO: 119 - 6294 IgG4P FALA Hole

EVQLVESGAELARPGASVKMSCKASGYTFTSYTMHWVKQRPGQGLEWIGYINPSSGYTEYNQKFKDKTTLTADKS
 SSTAYLQLSSLTSEDSAVYYCARVGDGFYPSWLAYWGQGTLLVTVSSASTKGPSVFPLAPCSRSTSESTAALGCLV
 KDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGKTYTCNVDHKPSNTKVDKRVESKYGP
 PCPPCPAPEAAGGPSVFLFPPKPKDTLMI SRTPEVTCVVVDVSQEDPEVQFNWYVDGVEVHNAKTKPREEQFNST
 YRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTSKAKGQPREPQVYTLPPSQEEMTKNQVSLSCAVKGFYP
 SDIAVEWESNGQPENNYKTTPVLDSDGSFFLVSRRLTVDKSRWQEGNVFSCSMHEALHNHYTQKSLSLGLGK

Antibody 645

SEQ ID NO: 120 - CDRH1	GIDLSNYAIN
SEQ ID NO: 121 - CDRH2	IIWASGTTFYATWAKG
SEQ ID NO: 122 - CDRH3	TVPGYSTAPYFDL
SEQ ID NO: 123 - CDRL1	QSSPSVWSNFLS
SEQ ID NO: 124 - CDRL2	EASKLTS
SEQ ID NO: 125 - CDRL3	GGGYSSISDTT

SEQ ID NO: 126 - antibody 645 VL region (gL5)

DIQMTQSPSS VSASVGDRVT ITCQSSPSVW SNFLSWYQQK PGKAPKLLIY EASKLTSQVP
 SRFSGSGSGT DFTLTISLQ PEDFATYYCG GGYSSISDTT FGGGTKVEIK

SEQ ID NO: 127 - antibody 645 VH region (gH4)

EVQLLESGGG LVQPGGSLRL SCAVSGIDLS NYAINWVRQA PGKGLEWIGI IWASGTTFYA
 TWAKGRFTIS RDNSKNTVYL QMNSLRAEDT AVYYCARTVP GYSTAPYFDL WGQGTLLTVSS

SEQ ID NO: 128 - antibody 645 VL region (gL5) - Cys

DIQMTQSPSS VSASVGDRVT ITCQSSPSVW SNFLSWYQQK PGKAPKLLIY EASKLTSQVP
 SRFSGSGSGT DFTLTISLQ PEDFATYYCG GGYSSISDTT FGGGTKVEIK

SEQ ID NO: 129 - antibody 645 VH region (gH4) - Cys

EVQLLES~~GGG~~ LVQPGGSLRL SCAVSGIDLS NYAINWVRQA PGK~~C~~LEWIGI IWASGTTFYA
TWAKGRFTIS RDNSKNTVYL QMNSLRAEDT AVYYCARTVP GYSTAPYFDL WGQGT~~LVTVSS~~

SEQ ID NO: 130 - 4133-6294-645 TrYbe heavy chain

QEQLVESGGGLVQPEGS~~LT~~LTCTASGFSFSGNYMCWVRQAPGKGLEWIGCLYTGSSGSTYYASWAKGRFTISK
SSTTVTLQMTSLTAADTATYFCARDLGYEIDGYGGLWGQGT~~LVTVSS~~GQPKAPSVFPLAPCCGDTPSSTVTLGCL
VKGYLPEPVTVTWNSGTLTNGVRTFPSVRQSSGLYSLSSVSVTSSSQPVT~~CNV~~AHPATNTKVDKTVAPSTCSKP
GGGGSGGGGSEVQLLES~~GGG~~LVQPGGSLRLSCAVSGIDLSNYAINWVRQAPGKCLEWIGIIWASGTTFYATWAKG
RFTISRDN~~SKNTVYL~~QMNSLRAEDTAVYYCARTVPGYSTAPYFDLWGQGT~~LVTVSS~~GGGGSGGGGSGGGGSGGGG
SDIQMTQSPSSVSASVGD~~RV~~TITCQSSPSVWSNFLSWYQQKPGKAPKLLIYEASKLTSGVPSRFSGSGSGTDFTL
TISSLQPEDFATYYCGGGYSSISDTTFGCGTKVEIK

SEQ ID NO: 131 - 4133-6294-645 TrYbe light chain

AQVLTQTPSPVSAVVGTVSISQASQSVYNNNNLSWYQQKPGQPPKLLIYDASKLASGVPSRFGSGSGTQFTL
TISGVQCDDAATYYCLGGYSSGWYFAFGGGTKVVVKRTPVAPT~~VLI~~FPPAADQVATGTVTIVCVANKYFPDVT
TWEVDGTTQTGTGIENSKTPQNSADCTYNLSSTLT~~LT~~STQYN~~SH~~KEYTCKVTQGTTSVVQSFNRGDCGGGGSGGGG
SEVQLVESGAELARPGASVKMSCKASGYTFTSYTMHWVKQRP~~GQ~~CLEWIGYINPSSGYTEYNQKFKDKTTLTADK
SSSTAYLQLSSLTSEDSAVYYCARVGDGFYPSWLA~~Y~~WGQGT~~LVTVSS~~GGGGSGGGGSGGGGSGGGGSDIQMTQSP
KFL~~LV~~SAGDRVTITCKASQSVRNDVAWYQQKPGQSPKLLIFYASKRYTGVPDRFTGSGYGTDFTTISTVQAEDL
AVYFCQQDYSSPTTFGCGTKLEIK

Figure 13(A)




Figure 13(B)




Figure 13(C)




Figure 13(D)




Figure 14




Figure 15




Figure 16




Figure 17




Figure 18(A)




Figure 18(B)




Figure 18(C)




Figure 18(D)




Figure 18(E)




Figure 18(F)




Figure 18(G)





Figure 19(A)



Note: From 2 replicates only

Figure 19(B)




Figure 19(C)




Figure 19(D)




Figure 19(E)




Figure 19(F)




Figure 19(G)




Figure 19(H)




Figure 19(I)




Figure 19(J)




Figure 19(K)




Figure 19(L)

